Massive Bio vs Mendel (2026)
Both find eligible patients in unstructured records, and they sell it differently. Massive Bio runs a matching service in oncology, where SYNERGY-AI extracts clinical and biomarker details from records and matches patients to more than 19,000 active trials, with oncology nurses reviewing each match and guiding enrollment. Mendel sells the technology rather than the service. Its Hypercube platform reads unstructured patient records for chart review, cohort building and trial prescreening, pairing large language models with symbolic reasoning over a clinical hypergraph and tracing every answer to highlighted evidence in the original record, and it can run in the customer's own environment. Massive Bio does the matching for you with nurses in the loop, while Mendel gives a health system or sponsor the tool to do its own. An oncology program that wants patients enrolled without building its own team starts with Massive Bio. One that wants its own staff running a platform across conditions starts with Mendel.
- It is a matching service, with oncology nurses and patient relations coordinators reviewing each match and guiding patients through enrollment against more than 19,000 active trials.
- Patients use it free through Patient Connect and the Ask Fiona assistant, physicians through Trial Relay, and drug makers buy recruitment reporting and analytics.
- A company led prospective study of 3,804 patients, published in 2026, reports an F1 of 0.82 for eligibility matching and screening time cut from about 120 to 30 minutes per patient.
- It is a platform your own team runs for chart review, cohort building and prescreening across conditions.
- Every answer is traced to highlighted evidence in the patient's original record, and the platform can be hosted in the customer's own environment.
- A randomized evaluation led by the University of Pennsylvania, published in Nature Communications in 2026, compared AI alone, human alone and combined prescreening.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Massive Bio and Mendel are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Massive Bio | Mendel |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2015 | 2016 |
| Headquarters | Boca Raton, Florida | San Jose, California, United States |
| Website | massivebio.com | mendel.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Oncology clinical trial matching and enrollment company based in Boca Raton, Florida. Its SYNERGY-AI platform extracts clinical and biomarker details from patient records and matches patients against more than 19,000 active oncology and hematology trials, with oncology nurses and patient relations coordinators reviewing matches and guiding patients through enrollment; Reticulum Nexus, launched in January 2026, coordinates the work through language model agents.
Source: AI Health Index, September 2026
Mendel, based in San Jose and backed by Oak HC/FT and DCM, sells Hypercube, a platform that reads unstructured patient records for chart review, cohort building and clinical trial prescreening. It pairs large language models with symbolic reasoning over the company's own clinical hypergraph, and ties every answer to highlighted evidence in the original record.
Source: AI Health Index, September 2026
Questions buyers ask
How do Massive Bio and Mendel work with the EHR?
For Massive Bio, the company's study describes health network deployments running on the network's own record data, with an oncologist-validated list returned to the record, and names no record system.
With Mendel, the platform ingests structured and unstructured sources spanning notes, pathology, genomics, claims, and electronic data capture. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How are Massive Bio and Mendel priced and sold?
In Massive Bio's case, the service is free to patients and caregivers; revenue comes from pharmaceutical, contract research and provider contracts, and the patient authorization discloses that a trial sponsor may pay the company for concierge, navigation and last-mile coordination once a patient pursues a specific trial. Products for drug makers (Trial Vision, the Drug Utilization Optimizer, NexusPulse) carry no published terms.
Mendel's AWS Marketplace listing sells Hypercube as software as a service on contract, with one listed dimension of $1,000,000 a month per Hypercube instance, and says pricing depends on the contract terms agreed with Mendel. The company argues that domain specific models can outperform generic large language models at a scalable cost, but no licensing structure or per record economics are disclosed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Massive Bio and Mendel handle patient data?
With Massive Bio, the privacy policy (last updated 04/06/2026) keeps patient profile data for ten years after collection or last activity and de-identified or aggregated data without a fixed term; the authorization runs ten years unless revoked, and revocation stops new processing of identifiable data within 30 days without reaching what was already used.
In Mendel's case, the platform is cloud agnostic and can be hosted inside the customer's own environment so patient data never leaves, and a dedicated capability de identifies PHI from clinical records. Evidence linking, where each answer traces to highlighted source text, functions as a safety control as well as a transparency one, since an unsupported assertion is visibly unsupported. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Massive Bio and Mendel?
For Massive Bio, the system reached F1 0.82 against 0.47 for GPT-4 zero-shot and 0.67 for GPT-4 chain of thought; screening time fell from a median 120 minutes to about 30 (15 automated, 15 clinical review), and median time to an oncologist-validated list was under 7 days. Ablations credit the knowledge graph and the split into agents.
With Mendel, the charts came from one health system and the trial was not powered for efficiency or subgroups. A second Penn study against the EA8191 prostate cancer trial (NCT06561230) is still running. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Massive Bio's F1 leaves out pairs with ambiguous timing, which were routed to clinician judgment, and at a sensitivity near 0.84 about one eligible pair in six was missed. Its terms say it maintains SOC 2 certification, while Mendel publishes no security attestation and no business associate terms for the case where it hosts the data. Neither publishes a rate card on its own site, and Mendel's AWS Marketplace listing shows one contract dimension of $1,000,000 a month per Hypercube instance.